Duke Center for Cerebrovascular Disease

Primary Affiliated Programs and Faculty

Neurology

Vani R. Chilukuri, MD *Neurointensive care, clinical research, clinical care
Larry B. Goldstein, MD *Neuropharmacology, clinical research, health policy
Carmen Graffagnino, MD *Neurointensive care, clinical research
Bradley J. Kolls, MD *Neurointensive care, clinical research
Daniel Laskowitz, MD *Cell biology, neurointensive care
E. Wayne Massey, MD Clinical stroke care
Joel Morgenlander, MD Clinical stroke care
Mark Skeen, MD Clinical stroke care

Subspecialty Certified in Vascular Neurology, American Board of Psychiatry and Neurology

Neuroendovascular Intervention

Tony P. Smith, MD
Gavin Britz, MD
David Enterline, MD
Ali Zimordi, MD

Neurosurgery
Allan H. Friedman, MD Neurosurgery
Takanori Fukushima, MD Vascular neurosurgery

Interventional Cardiology
J. Kevin Harrison, MD
Cary C. Ward, MD

Vascular Surgery
Richard L. McCann, MD

Diagnostic Neuroradiology
James M. Provenzale, MD, Chief, Diagnostic neuroradiology
Daniel Barboriak, MD
David Enterline, MD
James Eastwood, MD
Christopher Lascola, MD
Linda Gray-Leithe, MD
Jeffery Petrella, MD

Coagulation Disorders/ Thrombosis
Thomas L. Ortel, MD
Richard C. Becker, MD

Center for Clinical Health Policy Research
David B. Matchar, MD, Director, Stroke prevention policy
Gregory P. Samsa, PhD, Associate Director, Biostatics
Pamela W. Duncan, PhD, PT Clinical trials, physical therapy, poststroke recovery

Duke Institute for Genome Sciences and Policy
David B. Goldstein, PhD Genome science

Duke Multidisciplinary Neuroprotection Laboratory
David S. Warner, MD Director

The Multidisciplinary Neuroprotection Laboratories are dedicated to examining the pathophysiology of acute brain injury and defining therapeutic modalities for their treatment. Rodent models of focal and global cerebral ischemia, cardiopulmonary bypass, subarachnoid hemorrhage, and perinatal hypoxia/ischemia have been established with requisite control of relevant physiologic variables. Experimental protocols examine effects of catalytic antioxidants, human apolipoprotein E isoforms, allosteric modifiers of hemoglobin/oxygen affinity, glutamate/glycine antagonists, and anesthetic agents on behavioral/histologic outcome. Neurochemical and molecular biological procedures are used to define drug/gene effects on biochemical sequelae to acute injury. Transgenic/knockout species are particularly important in this work. Primary neuronal/glial cultures are used to define cellular responses to oxidative and excitotoxic stresses with emphasis on supporting cell viability. Researchers from both the basic and clinical neurosciences are integrated in this work